Background. Enterococci are an important cause of healthcare-associated infections. We retrospectively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-sensitive enterococci (VSE) infections.
Enterococci are a significant component of the normal bacterial flora of the lower gastrointestinal tract and other mucocutaneous surfaces. Although they are of low virulence in healthy immunocompetent individuals, enterococci are the third leading cause of healthcare-associated infections in the United States, with 29% of isolates being resistant to vancomycin [1] . Vancomycin-resistant enterococci (VRE) are commonly isolated from blood and other sites in recipients of hematopoietic stem cell transplantation (HSCT) [2] [3] [4] [5] [6] [7] , with directly attributable mortality of preengraftment VRE bloodstream infections (BSIs) recently reported at 9% [6] . Given the complex medical condition of recipients of allogeneic HSCT, it is often difficult to attribute mortality between several coexistent causes. VRE infection may actually serve as a marker of concomitant severe illness [4] . We retrospectively reviewed cases of enterococcal bloodstream infections among allogeneic HSCT recipients at the University of Minnesota and analyzed risk factors for enterococcal BSI and the association of these infections with outcomes.
METHODS

Patients and Data Collection
Patients receiving their first allogeneic HSCT at the University of Minnesota between 1 January 2004 and 31 December 2008 were included in the study. Demographic information, transplant characteristics, infection dates, and outcomes were obtained from the University of Minnesota Blood and Marrow Transplant Database, which contains prospectively collected data on all patients receiving transplantation at our center including episodes of clinically significant infections treated at the University of Minnesota and outside facilities. Patients' electronic medical records were reviewed to verify the information on infection episodes, and sensitivity to vancomycin was recorded. Data were censored at relapse of underlying disease or second allogeneic transplant. Survival status was known for all patients included in the study. The study was reviewed and approved by the University of Minnesota Institutional Review Board.
VRE Screening
All patients admitted to the blood and marrow transplant unit were screened at admission for VRE by culture using perirectal swabs. Surveillance cultures were then performed periodically, generally weekly, throughout the initial hospitalization. The ongoing VRE surveillance included only hospitalized patients, except as clinically indicated. Patients who were found to be colonized or infected with VRE were placed under contact isolation.
Blood Cultures
Blood cultures were drawn through a tunneled central venous line or peripherally inserted central catheter in all patients with new onset of fever or with other signs of infection, at the discretion of treating physicians. After the initial positive blood culture, blood cultures were generally drawn daily until 2 consecutive cultures were negative and the patient had defervesced.
Definitions
Enterococcal bloodstream infection was defined as any blood culture growing Enterococcus species [8] . For this analysis, an Enterococcus isolate was considered vancomycin resistant if it had a minimum inhibitory concentration (MIC) of ≥32 µg/mL. The isolates were considered vancomycin sensitive if they had an MIC of ≤8 µg/mL.
Patients who developed a VRE BSI at any time during the first 365 days after transplant were included in the "VRE BSI" group. Patients who developed a BSI with vancomycinsensitive enterococci (VSE), but never developed a VRE BSI in the first year, were placed in the "VSE BSI" group. Patients who never had an enterococcal BSI were included in the "No enterococcal BSI" group. Patients who had VRE isolated from a surveillance culture or from any other nonsterile body site were considered to be VRE colonized.
Patients without neutrophil recovery to >500/μL by day 42 were considered to have graft failure.
Statistical Methods
For descriptive tables, frequencies and incidence rates were calculated. Comparisons among groups were made using the χ 2 test, Fisher exact test, or Wilcoxon test. Kaplan-Meier and cumulative incidence estimates were made for overall survival and nonrelapse mortality, respectively. Analyses used a followup period of 1 year and no patients were lost to follow-up. Multivariate Cox regression was used to determine risk factors for the cause-specific hazards of VRE and VSE BSI, using time-dependent covariates for colonization, graft-vs-host disease (GVHD), and engraftment. This method has been used in other studies [9, 10] to analyze time-dependent risk factors in the presence of a competing hazard of death. An alternative method, Fine and Gray regression, which does not allow for time-dependent risk factors, was also tested and showed good agreement with the Cox model for non-timedependent factors (not reported). Multivariate Cox regression was used to test the association of BSI with 1-year overall survival, using time-dependent covariates for VRE BSI, VSE BSI, GVHD, engraftment, and colonization [11] [12] [13] . Multivariate logistic regression was used to analyze risk factors for colonization either before or after transplant.
RESULTS
Seven hundred fifty-two patients underwent their first allogeneic transplant within this 5-year timeframe. The median followup was 47 months, with a minimum follow-up of 1 year. Patient and transplant characteristics are shown in Table 1 .
Colonization
Overall, 173 (23%) of patients were colonized with VRE throughout the study period. Of these, 25% had been known to be VRE colonized prior to their transplant. Figure 1 ). We observed no trend in age or diagnoses over the 5 years of study to account for the increase in colonization.
Incidence of and Risk Factors for Enterococcal Bloodstream Infections
Ninety-three patients had enterococcal BSIs during the first year following transplantation. Overall, 14% (95% CI, 9.6%-21%) of patients colonized with VRE developed VRE BSI, whereas the incidence of VRE bacteremia was only 4% (95% CI, 2.8%-6.3%) in the noncolonized group. The cumulative incidence of first enterococcal BSI in the presence of the competing risk of death was 6.6% (95% CI, 4.8%-8.4%) and 5.7% (4.0%-7.4%) for VRE and VSE BSI, respectively, during the first year after transplantation. Most of the infections occurred in the first 60 days as shown in Figure 2 . None of the patients with VSE bacteremia subsequently developed a VRE bacteremia. Although the rates of VRE colonization were increasing throughout the study period, the incidence of VRE BSI among colonized patients decreased significantly, resulting in similar rates of VRE BSI incidence ( Figure 1 ). Rates of vancomycin resistance among bloodstream isolates were 66% and 31% in adults and children, respectively. Risk factors for acquiring a VRE BSI are presented in Table 2 . Colonization with VRE, delay in engraftment, and None of the risk factors tested was associated significantly with VSE bacteremia, including acute and chronic GVHD, time to engraftment, age, underlying diagnosis, and conditioning regimen.
Outcome of Patients With Enterococcal Infections
In adult patients, the all-cause mortality 30 days after the onset of BSI was 38% for both VRE (95% CI, 25%-54%) and VSE (95% CI, 21%-62%) bacteremia. In pediatric patients, the 30-day mortality was 20% (95% CI, 5.4%-59%) and 4.5% (95% CI, .6%-28%) for VRE and VSE BSI, respectively (P = .22). Median time to resolution of BSI (first of the 2 consecutively negative blood cultures after infection) was 3 (range, 1-14) and 1 (range, 1-10) days in VRE and VSE BSI, respectively (P = .001). Overall survival at 1 year after onset of BSI in adults was 20% (8 of 40) and 48% (10 of 21) for VRE and VSE BSI, respectively (P = .04). In pediatric patients, 1-year survival was 60% (6 of 10) and 86% (19 of 22) for VRE and VSE BSI, respectively (P = .17). We did not observe a statistically significant difference in overall survival 1 year after infection between VRE BSI occurring before and after day 60 (25% and 13% for early and late infections, respectively, P = .43). Overall survival and nonrelapse mortality at 1 year after transplant are summarized in Table 3 and were inferior among patients who acquired VRE BSI compared to the other groups. In a multivariate analysis of survival during first year after transplant, VRE and VSE bloodstream infections were associated with relative increase in the mortality rate of 4.2 (95% CI, 3.1-6.9) and 2.3 (95% CI, 1.4-5.1), P < .01), respectively. Enterococcal bacteremia and time to engraftment (in 1-week intervals) were the only other variables significantly associated with survival in this analysis (Table 4) .
DISCUSSION
This study describes a large cohort of HSCT patients with enterococcal BSI. Several observations have emerged from this study. First, VRE colonized patients had a higher risk of developing VRE bloodstream infection than patients not colonized, in line with previous reports in patients with cancer and other conditions, reviewed in [14] . Second, the risk of developing a VRE bacteremia increased with each week's delay in engraftment, and was highest for those not engrafted by day 42. Third, the rate of resistance was substantially higher for adult patients than pediatric patients. Fourth, VRE BSI was associated with inferior overall survival at 1 year after transplant. And finally, both VRE and VSE bloodstream infections occurred at similar rates throughout the first year after transplant. Vancomycin-resistant enterococci have emerged as important pathogens in healthcare-associated infections over the last 2 decades [14] [15] [16] [17] , with reported rates of vancomycin resistance among invasive isolates of Enterococcus faecium varying internationally from 0% to 35% in 2009 [1, 18] . This cohort had a 7% rate of VRE bacteremia in the first year following HSCT, although VRE-colonized patients developed BSI at a rate of 14%. Most of these infections occurred during the preengraftment period at a rate similar to previous reports [4, 6] ; the high-risk period in our cohort extended to approximately day 100 after HSCT.
The rate of vancomycin resistance for enterococcal bloodstream isolates among our adult patients was 66%, whereas the isolates from pediatric patients had a lower resistance rate of 38%. During the period of study, these patient groups were housed 1 floor apart. The hospital has an antimicrobial stewardship program that restricts vancomycin use for both adult and pediatric patients after 48-72 hours of use. While restriction of vancomycin use has been suggested as a means of reducing the rate of VRE infections, a systematic review [19] was not able to confirm this effect. In our patient cohort, 23% of allogeneic HSCT patients were colonized with VRE, with 25% of those having confirmed colonization prior to their transplant based on either admission cultures or cultures performed during previous hospitalizations at our center. This is in agreement with previously reported rates of colonization in HSCT patients [6, 20, 21] and other medical or surgical patients in the United States [16, 22] . Barrier precautions and contact isolation have not been clearly shown previously to be effective in preventing VRE colonization [23, 24] but are widely used in HSCT recipients.
We found equivalent, but disturbingly high, all-cause mortality 30 days after infection in patients with VRE and VSE bacteremia. We speculate that this mortality is not directly attributable to enterococcal bacteremia per se, but rather that the enterococcal BSIs preferentially occur in patients with delayed engraftment and other significant medical conditions. During the management of fever at our center, standard procedure is to use vancomycin, ceftazidime, and often tobramycin as empirical antimicrobial therapy until results of blood, urine, and sputum cultures are obtained. VRE therapy will be added after VRE is isolated from culture, and therapy is refined once the sensitivity profile is available. In patients known to be colonized with VRE, VRE-specific therapy will be added once a culture is identified as containing grampositive cocci in chains. The number of events in our study is not high enough to detect a potential difference in outcome caused by the later addition of VRE therapy at the time of identification of a VRE pathogen compared with VSE, which are covered by the empirical antimicrobial therapy. A metaanalysis of studies of mortality associated with VRE vs VSE infections, which controlled for underlying severity of illness, found a higher risk of mortality in patients with VRE infections [25, 26] . However, most of the studies included in the metaanalysis were published before widespread availability of antibiotics active against VRE. A recently published analysis of outcome of VRE BSI in a mixed patient population from a tertiary care institution showed a short-term mortality rate similar to our cohort [27] . We did not evaluate directly attributable mortality caused by enterococcal BSI because of high prevalence of concomitant medical conditions, which make such attribution in HSCT patients subjective and arbitrary. While the extent of direct contribution of enterococcal infections to negative outcome has been a matter of debate, the association of these infections with morbidity and mortality has been demonstrated previously in HSCT and hematologic malignancies [20, 26, 28, 29] , solid organ transplantation [30] , and other patients [16, 17, [31] [32] [33] [34] [35] . Our findings of similar short-term mortality of VSE and VRE bacteremia, but increased nonrelapse mortality at 1 year after HSCT of the VRE vs VSE vs "no enterococcal bacteremia" groups, support the opinion that VRE infections may serve as a marker of severity of underlying medical condition. In contrast to nonopportunistic bacterial pathogens, enterococcal infections rarely present with shock, pneumonia, or other end-organ damage clearly linked with morbidity and mortality. Further experimental and clinical studies are needed to elucidate pathogenesis of enterococcal infections and their contribution to outcome in light of mortality that is similar to that of bacteremia caused by organisms known to be more virulent. In summary, we have observed a high rate of vancomycin resistance among bloodstream enterococcal isolates, which underscores a need for development of new strategies to combat VRE infections of sterile sites. Periodic surveillance for VRE colonization can indicate patients for whom anti-VRE antibiotics should be included in their empiric therapy or neutropenic fever, or at least for prompt initiation on identification of gram-positive cocci in cultures taken from an otherwise sterile site. The clinical utility of such an approach needs further investigation.
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